Diabetes Australia has welcomed confirmation that the supply of Ozempic (semaglutide) in Australia has stabilised, with prescribing and supply restrictions now lifted.
Pharmaceutical company Novo Nordisk has advised the Therapeutic Goods Administration (TGA) that national stocks have improved to the point where doctors can now prescribe Ozempic for new patients, and treatment can continue as normal for existing patients. This follows a prolonged global shortage that began in 2022 due to an unexpected increase in demand.
Ozempic is subsidised under the Pharmaceutical Benefits Scheme (PBS) for the treatment of type 2 diabetes when specific clinical criteria are met. It is not subsidised for weight loss or other off-label uses. A separate brand, Wegovy, also contains semaglutide but is approved only for chronic weight management and cardiovascular risk reduction in people without diabetes.
The TGA has also advised that a new 3 mL pen is replacing the previous 1.5 mL version of the Ozempic 0.25 mg/0.5 mg pre-filled pen. Further information is available through the TGA and Novo Nordisk.
While supply is improving, it may take time for some local pharmacies to restock. If Ozempic is unavailable, pharmacists are encouraged to contact their wholesalers or Novo Nordisk for delivery updates. Patients can also speak with their pharmacist about when stock will arrive.
Diabetes Australia will continue to monitor the supply of semaglutide medicines and support Australians living with type 2 diabetes to access their treatment. Patients are encouraged to speak with their doctor or pharmacist if they have questions about their medication.
